Skip to main content

Advertisement

Table 3 Adverse events

From: Baseline urate level and renal function predict outcomes of urate-lowering therapy using low doses of febuxostat and benzbromarone: a prospective, randomized controlled study in a Chinese primary gout cohort

  Febuxostat N = 105 Benzbromarone N = 109 Total N = 214
Gout flare 24 (22.85) 37 (33.94) 61 (28.50)
 Once 17 (16.19) 26 (23.85) 43(20.09)
 Twice 5 (4.76) 11 (10.09) 16 (7.48)
 More than twice 2 (1.90) 0 2(0.93)
Transaminase elevation from normal 35(33.33) 26 (23.85) 61 (28.50)
 1~2 × ULN 25 (23.81) 22 (20.18) 47 (21.96)
 2~3 × ULN 9 (8.57) 3 (2.75) 12 (5.61)
 > 3 × ULN 1 (0.95) 1 (0.92) 2(0.93)
New-onset CKD based on CCr 0 4 (3.67) 4 (1.87)
 CCr: 50–80 mL min−1 1.73 m−2 0 4 (3.67) 4 (1.87)
 CCr: < 50 mL min−1 1.73 m 0 0 0
Cardiovascular events 0 0 0
Skin reaction 0 0 0
Other adverse events 0 0 0
  1. Data presents the number of patients (percentage). ULN upper limit of normal